BioXcel Therapeutics Inc (NASDAQ:BTAI) Director Peter Mueller purchased 4,007 shares of the company’s stock in a transaction on Tuesday, December 4th. The shares were bought at an average cost of $5.13 per share, with a total value of $20,555.91. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.
Shares of NASDAQ:BTAI traded up $0.20 during midday trading on Thursday, reaching $5.06. The company’s stock had a trading volume of 17,000 shares, compared to its average volume of 41,960. BioXcel Therapeutics Inc has a 1 year low of $4.65 and a 1 year high of $14.79.
BioXcel Therapeutics (NASDAQ:BTAI) last announced its quarterly earnings data on Friday, November 9th. The company reported ($0.31) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.26) by ($0.05). On average, research analysts anticipate that BioXcel Therapeutics Inc will post -1.12 earnings per share for the current fiscal year.
Several equities analysts have weighed in on BTAI shares. Zacks Investment Research raised BioXcel Therapeutics from a “hold” rating to a “buy” rating and set a $10.00 price target for the company in a research report on Tuesday, August 14th. Canaccord Genuity reissued a “buy” rating and set a $21.00 price target on shares of BioXcel Therapeutics in a research report on Friday, August 10th. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. BioXcel Therapeutics currently has a consensus rating of “Buy” and a consensus target price of $18.67.
BioXcel Therapeutics Company Profile
BioXcel Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on novel artificial intelligence-based drug development in the fields of neuroscience and immuno-oncology in the United States. The company is involved in developing BXCL501, a sublingual thin film formulation of dexmedetomidine designed for acute treatment of agitation resulting from neurological and psychiatric disorders; and BXCL701, an immuno-oncology agent designed for the treatment of prostate and pancreatic cancers.
Read More: Put Option
Receive News & Ratings for BioXcel Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioXcel Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.